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1. Introduction 
Homocysteine (Hcy) is a non-protein amino acid resulting from the demethylation of the 
essential amino acid methionine. This is an important step in the metabolism of nucleic 
acids, fats and high-energy bonds and for this reason, the transmethylation reaction of Hcy 
back to methionine requiring Vitamin B12 and folic acid, is equally important. This pathway 
is dependent on a form of folate produced by methylenetetrahydrofolate reductase 
(MTHFR). Hcy can also be metabolised to cystathionine, an intermediate of the non-essential 
amino acid cysteine. Vitamin B6 is necessary for this transulphuration reaction to occur 
(Figure 1) (Warsi et al, 2004; Guilliams, 2004; Moroz et al, 2007; Castro et al, 2006)  
Excess levels of Hcy are excreted to the plasma where the liver and kidney are the organs 
achieving catabolism and excretion of Hcy. Despite this, mild hyperHcy is present in 5-7% 
of the general population, due to either inherited or acquired dietary deficiencies of vitamin 
B6, B12 and folic acid. Other causes include renal failure, malignancy, hypothyroidism and 
use of folate and vitamin B6 antagonists (Halazun et al, 2007).  
 
 
Fig. 1. Brief summary of homocysteine metabolism 
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2. Historical perspective 
HyperHcy has been linked to vascular disease since the early 1960’s when children with 
mental retardation, accelerated growth and propensity to arterial and venous thrombosis 
were found to have homocysteinuria. An emerging pattern of atherosclerosis was detected 
in these patients and it was concluded that genetic defects in homocysteine metabolism and 
associated homocysteinuria was responsible for these vascular lesions (Guilliams, 2004).  
Endothelial vascular injury and atherosclerosis was subsequently demonstrated through 
intravenous infusion of Hcy in an animal model (Warsi et al, 2004).  
Several studies followed this, reporting the association between Hcy concentrations and 
vascular disease and more recent large scale meta-analyses have supported these findings 
(Castro et al, 2006). A causal relationship between homocysteine and cardiovascular disease 
is felt to be highly likely and hyperHcy is now an established modifiable risk factor for 
cardiovascular disease. Raised Hcy levels are present in significant numbers of patients with 
peripheral, cerebrovascular and coronary heart disease (CHD). High values have also been 
proven to predict the failure of vascular intervention and more rapid progression of CHD 
and peripheral vascular disease (Halazun et al, 2007).  
3. Evidence for homocysteine in aneurysmal disease 
While the importance of homocysteine in atherosclerotic disease has been established, there 
is also evidence to suggest that raised Hcy levels could play a role in the pathogenesis of 
abdominal aortic aneurysm (AAA).  
A number of recent studies have demonstrated the prevalence of raised Hcy levels in AAA 
to be as high as 50% and one study has demonstrated a link between Hcy levels and the rate 
of expansion of AAA (Halazun et al, 2007). Despite this, data is still relatively limited. 
Confounding has not been excluded with male sex, smoking, hypertension and raised low-
density lipoprotein levels all shown to be independently associated with AAA (Naydeck et 
al, 1999), while the possibility of reverse causality needs consideration. Current large scale 
genotypic studies are attempting to deal with this and will be discussed later in the chapter.  
4. How does homocysteine contribute to aneurysmal disease 
Their is no doubt that the pathogenesis of AAA is multi-factorial, in brief, the degradation of 
key structural proteins such as elastin and collagen results in weakening of the aortic wall 
and subsequent dilatation and aneurysm formation. HyperHcy has been shown to enhance 
this process through several mechanisms. 
4.1 Oxidative damage and thrombogenicity 
Homocysteine has been shown to cause endothelial dysfunction through mechanisms felt to 
be attributable to oxidative stress. This is an important event preceding manifestation of 
vascular disease and its involvement is strengthened by the fact that administration of 
antioxidant vitamins can prevent the impairment of endothelial vasodilator function 
induced by experimental hyperHcy (Stuhlinger et al, 2003).  
One such mechanism is the impaired production of nitric oxide (NO) as an effect of 
hyperHcy. This is possibly through increasing levels of asymmetric dimethylarginine 
(ADMA), a strong inhibitor of endothelial nitric oxide synthase (Guilliams, 2004; Stuhlinger 
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et al, 2003). NO contributes to vessel homeostasis by inhibiting vascular smooth muscle 
contraction and growth, platelet aggregation, and leukocyte adhesion to the endothelium. 
The resultant over-production of oxidative free radicals has been shown to induce intimal 
injury, activate elastase and increase calcium deposition (Brunelli et al, 2000).  
The toxic effects of hyperHcy on the endothelium extend to the prothrombotic environment 
that is created at several levels. These include increased platelet aggregation, activation of 
clotting factors V, X and XII, along with depressed activation of protein C and cell surface 
thrombomodulin and modulation of tissue plasminogen activator binding to its cell surface 
receptor, annexin II (Perna et al, 2003).  
4.2 Elastolysis and proteolysis 
While the above mechanisms are undoubtedly contributors to aneurysm formation, there is 
strong evidence to suggest that hyperHcy can enhance proteolysis and this maybe 
particularly relevant to the pathogenesis of AAA. In the normal aorta, arterial wall 
structures elastin, collagen and smooth muscle bear the vast majority of wall stress and act 
as a strong almost indistensible safety net to limit expansion. Histological features of 
aneurysmal aortic wall show failure of this safety net by way of elastin fragmentation and 
degeneration, collagen degradation, a medial attenuation and a reduction in tensile strength 
(Arapoglou et al, 2009). 
4.2.1 Serine elastase 
Serine elastase is a member of a large family of protein-cleaving enzymes (proteases) that play 
an essential role in processes like blood coagulation, apoptosis and inflammation. Regulation 
of proteolysis induced by these serine proteases is essential to prevent self-induced damage. 
Vascular smooth muscle cells (VSMC’s) are felt to contribute to the homeostasis of the vessel 
wall by synthesising elastin and elastinolytic enzymes. HyperHcy has been demonstrated to 
induce the synthesis of serine elastase in vascular smooth muscle cells. While the 
mechanism for this is currently unclear, through the activation of serine elastase, Hcy 
increases the rate of elastoylsis and subsequent degradation of the extra-cellular matrix. The 
associated release of elastin peptides are chemotactic for VSMC’s which then proliferate and 
migrate into the sub-endothelium, resulting in neointimal formation and progressive 
vascular occlusion. This suggests a possible mechanism to explain the proposed link 
between aneurysmal and atherosclerotic disease. Such a mechanism is supported by studies 
demonstrating that inhibition of serine elastase limits the fragmentation of elastic laminae in 
the aortic wall while also preventing the VSMC alterations and the associated progressive 
vascular disease (Jourdheuil-Rahmani et al, 1997).  
4.2.2 Matrix metalloproteinases 
Abdominal aortic aneurysm (AAA) development and expansion are multifactorial in 
pathogenesis (Ailawadi et al, 2003). Inflammatory response plays a significant role in the 
pathogenesis of development and expansion of aneurysm. Normal aorta undergo a constant 
remodelling pocess involving various proteases that degrade elastin and collagen, and the 
production of new elastin and collagen by the smooth muscle cells of the aortic wall. 
Disturbance of the normal balance in this process results in AAA initiation and expansion 
(Davies, 1998; Grange et al, 1997). Three proteolytic systems seem to be involved in the 
degradation of aorta (Lindholt et al, 2003). 
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 The serine-dependent proteases are elastases that degrade elastin in the aorta 
 The cysteine-dependent proteases are lysosomal proteases such as cathepsin K, L, S that 
plays a role in apoptosis of the smooth muscles cells of aorta 
 The metalloproteinases (MMP) are elastases and collagenases that degrade aortic elastin 
and collagen. Elastin degradation is associated with aneurysm initiation and expansion 
and collagen destruction is responsible for eventual AAA rupture. 
MMPs are the most widely studied proteolytic system in the pathogenesis of AAA. Many 
MMPs have been implicated in the pathogenesis of AAA including MMP-1, MMP-2, MMP-
3, MMP-8, MMP-9, MMP-12, MMP-13 and MMP-14(Wilson et al, 2005a; Longo et al, 2005; 
Wilson et al, 2005b; Tromp et al, 2004). MMP-9 is an elastase most frequently implicated in 
the aneurysm initiation, expansion and rupture. MMP-9 knockout mice do not form 
aneurysm and their ability to form aneurysm is restored after wild type bone marrow 
transplantation (Pyo et al, 2000). MMP-9 has also been implicated in asymmetrical regional 
wall expansion in the anterior wall of aorta (Sinha et al, 2006). Its level in ruptured AAA has 
been found to be significantly higher than large AAA (Petersen et al, 2000). MMP-2 and 
MMP-12 (macrophage elastase) are elastases that are also found in increased concentration 
in aneurysmal aortic tissue. High concentration of MMP-2 is found in small AAA suggesting 
its role in early AAA formation (Crowther et al, 2000). MMP-12 is highly expressed in tissue 
along the leading edge of AAA suggesting a role in AAA initiation (Warsi et al, 2004). 
MMP-1, MMP-3, MMP-8, MMP-13 are collagenases involved in degradation of extracellular 
matrix during aortic wall remodelling (Tromp et al, 2004; Pyo et al, 2000; Sinha et al, 2006; 
Petersen et al, 2000; Crowther et al, 2000; Abdul-Hussien et al, 2007). MMP-14 is a 
membrane type MMP expressed at cell surface and is responsible for activation of MMP-2 
(Apte et al, 1997). The exact mechanism of MMPs interactions with other inflammatory 
cytokines, inflammatory cells, microbes and aortic wall tissue is unknown. MMPs can be 
activated by a range of stimuli including other MMPs, cytokines released by the 
inflammatory cells, elastin degradation products, microbes such as chlamydiae pneumoniae, 
reactive oxygen species, and mechanical alteration in the aortic wall stress (Warsi et al, 
2004).  
Several genetic polymorphisms are associated with MMP and some have been linked with 
increased frequency in AAA (Thompson et al, 2008; Sandford et al, 2007). Genetic 
polymorphism is a difference in DNA sequence among the population that gives rise to 
different forms such as in the case of human blood groups. Its occurrence cannot be 
accounted for by just recurrent mutation and is present in greater than 1% of the population. 
MMP-9 polymorphism has been implicated in AAA. A cytosine to thymidine substitution in 
position 1562 of the promoter region (MMP-9 -1562C>T) produces a 1.5 fold increase in 
promoter activity (Zhang et al, 1999). Jones et al. reported increased frequency of TT and CT 
genotypes in people with AAA compared to normal population (Jones et al, 2003). 
However, other studies on MMP-9 had not demonstrated similar genetic predisposition 
(Yoon et al, 1999; Higashikata et al, 2004). Platelet activating factor (PAF) can induce MMP-
1, MMP-2, and MMP-9 transcription. The activity of PAF is regulated by PAF 
acetylhydrolase (PAF-AH). A guanine to thymidine substitution in position 994 of the exon 
9 (PAF-AH +994 G>T) results in lower enzymatic activity of PAF-AH with increased PAF 
level. GT and TT genotype are associated with AAA with an odd ratio of 2.48 (CI 1.36-4.65) 
(Thompson et al, 2008). In general there is a lack of clear evidence that upregulation of 
MMPs in AAA has a genetic basis (Sandford et al, 2007). 
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Dampening the overactivity of MMPs in AAA can potentially slow the progression of AAA. 
Recent review in the area suggest that statins, non steriodal antiinflammatory drugs 
(NSAIDS) and antibiotics hold the most promise (Bergqvist et al, 2011). Statin has been 
shown in metaanalysis to be beneficial in slowing the expansion of AAA (Takagi et al, 2010). 
The median expansion rate decreased by about 1.2mm per year. Aortic tissue obtained at the 
time of surgery has shown a reduction in the level of MMP-3 and MMP-9 for patients who 
are taking statin (Wilson et al, 2005a). The evidence for antibiotics and NSAIDS is less 
convincing. Roxythromycin and doxycycline have been shown to modulate MMP 
concentrations and were associated clinically with decreased aneurysm expansion rate in 
some studies but not others (Hogh et al, 2009; Karlsson et al, 2009; Morosin et al, 2001; 
Vammen et al, 2001). NSAID’s reduce the release of cytokines (IL-1β and IL-6) and in turn 
reduce the production of elastases in rat aortic tissue (Parodi et al, 2006). A case control 
study shows that it potentially can reduce AAA expansion rate (Lindholt et al, 2008).  
4.2.3 Tissue Inhibitors of MMP’s and plasminogen activator Inhibitors 
Regulation of the MMP system is provided by Tissue Inhibitors of Metalloproteinases 
(TIMP’s) and Plasminogen Activator Inhibitors (PAI’s), which inhibit the action of plasmin 
(an MMP activator). Platelet Activating Factor (PAF) has been shown to induce MMP 
formation.  
An imbalance of MMP’s and their inhibitors/activators leads to an excess of MMP’s 
resulting in the degradation of the structural proteins elastin and collagen and subsequent 
aneurysm formation (Thompson et al, 2008; Sandford et al, 2007).  
Polymorphisms have been identified in the genes encoding each of these protein systems. A 
relative decrease in TIMP expression has been found in aneurysmal aortas. Although this 
study concluded that this deficiency was not a result of a primary gene mutation (Tilson et al, 
1993), more recent studies have identified both a TIMP-1 and TIMP-2 polymorphism to be 
expressed in higher frequencies in patients with AAA (Ogata et al, 2005; Wang et al 1999). 
Despite this, the observed single base pair change does not change translation and is therefore 
unlikely to be involved in the pathogenesis of AAA. It does however, raise the possibility that 
other polymorphisms identified within the TIMP gene (G418C and C177T), maybe linked to 
AAA formation (Sandford et al, 2007), although this has not been investigated to date. 
Polymorphisms of both PAF and PAI genes have also been linked to AAA. A 5G allele in 
position 675 of the PAI-1 gene is associated with reduced transcription and is expressed 
more frequently in patients with a family history of AAA (Rossaak et al, 2000). Those 
patients with homozygosity for the 5G allele were found to have more rapid rates of 
aneurysmal expansion (Jones et al, 2002).  
PAF acetylhydrolase controls the activity of PAF. A common polymorphism (G994T) in this 
gene reduces enzyme activity and results in increased levels of PAF. A significant 
association with the T-allele and AAA has been demonstrated (Thompson et al, 2008).  
4.2.4 Fibrillin 
In addition to the mechanisms described above, in a process known as homocysteinylation, 
Hcy can damage elastin and other matrix proteins through non-enzymatic chemical 
reactions resulting in protein inactivation (Moroz et al, 2007).  
Firbrillin is a glycoprotein essential for the formation of elastic fibres found in connective 
tissue. It is secreted into the extracellular matrix by fibroblasts and becomes incorporated 
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into the insoluble microfibrils which appear to provide a scaffold for the deposition of 
elastin (Kielty et al, 2002).  
Fibrillin appears to be particularly susceptible to the process of homocysteinylation. This 
involves a post-biosynthetic acylation of free amino groups in proteins and is mediated by 
Hcy thiolactone, an intermediate of Hcy metabolism. It is felt that the epidermal growth 
factor (EGF)-like domains found in fibrillin are preferential sites of homocysteinylation 
(Krumdieck & Prince, 2000).  
The effect of homocysteinylation is protein damge with an altered electrophoretic mobility 
and loss of enzymatic activity through protein denaturation. This essentially renders the 
protein useless and may result in elastolysis and damage to other matrix proteins. 
When we consider that Marfans syndrome is due to a mutation in the fibrillin 1 (FBN1) gene 
and the clinical manifestations include aortic aneurysmal disease, it strengthens the 
evidence that the toxic effects of hyperHcy and associated homocysteinylation of fibrillin, 
are directly implicated with AAA formation. 
5. Genetic polymorphisms and homocysteine 
There is increasing evidence supporting an inheritable component to AAA. Although 
several factors, including age, vitamins and hormones can influence plasma Hcy levels, 
candidate gene analysis has recently demonstrated that mutations in genes coding for 
enzymes involved in Hcy metabolism may also play a role in HyperHcy and subsequently 
the pathogenesis of AAA. 
5.1 MTHFR gene 
As mentioned previously, the metabolism of Hcy requires several enzymes, nutrient co-
factors and a methyl donor. Genetic control of all of these pathways is essential, however, as 
with any gene their are inherited or acquired errors that effect the efficiency by which Hcy 
can be metabolised. 
The most common of these errors are felt to occur in the gene encoding for the enzyme 
MTHFR. This enzyme catalyses the conversion of 5,10-methylenetetrahydrofolate to 5-
methyltetrahydrofolate, a cosubstrate for Hcy remethylation to methionine. 
Currently, 33 MTHFR gene mutations have been reported as causing severe hyperHcy. 
Perhaps more clinically relevant to aneurysmal disease is a polymorphism in the MTHFR 
gene at the 677 locus which involves substitution of a cytosine nucleotide for a thymine 
(Strauss et al, 2003; Jones et al, 2005; Khandanpour et al, 2009; Sunder-Plassman & Fodinger, 
2003; Klerk et al, 2002). It is subsequently referred to as the T-allele. This polymorphism 
leads to an alanine to valine change in the enzyme, resulting in 55-65% loss of enzyme 
activity. Individuals who are homozygous for the T-allele (TT homozygous) are most likely 
to manifest this level of enzyme inactivity, while those who are CT heterozygous will 
experience only 25% loss of activity compared to a CC homozygous individual (Guilliams, 
2004).  
The frequency of the T allele exhibits marked geographic variability. In those of African 
descent the frequency is <1%, ranging to >20% in the Hispanic population. The frequency of 
TT homozygotes shows similar variability (Castro et al, 2006).  
The homozygous and heterozygous genotypes (CT) and (TT) have been shown to be 
associated with raised Hcy levels and lower MTHFR enzyme concentrations. In one study 
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there was a 36% difference in mean Hcy levels between wildtype and TT genotypes 
(Khandanpour et al, 2009), while a 47% difference was demonstrated in another study 
(Rassoul et al, 2000). Further to this, a strong association has been demonstrated between the 
TT genotype, hyperHcy and coronary, cerebro and peripheral atherosclerotic disease 
(Khandanpour et al, 2009; Klerk et al, 2002; Moat et al, 2004). Significantly, the association of 
the MTHFR genotype with Hcy levels is only observed when concomitant inadequate folate 
concentrations are present (Guilliams, 2004; Castro et al, 2006), although low folate levels 
independent of MTHFR have not been shown to cause hyperHcy (Spark et al, 2003).  
Several studies have investigated the link between MTHFR gene polymorphisms and AAA 
(Brunelli et al, 2000; Jones et al, 2002; Strauss et al, 2003; Ferrara et al, 2006). All but one of 
these demonstrated a link between the T allele polymorphism and AAA, a meta-analysis of 
these studies confirmed a significant effect in favour of the T-allele variant increasing the 
risk of AAA (Thompson et al, 2008). Interestingly, the study that did not provide evidence to 
suggest a link between the T-allele and AAA, did suggest that it may be a contributory 
factor in AAA severity as indicated by aneurysm size (Strauss et al, 2003). This is consistent 
with results suggesting that hyperHcy patients have faster expansion rates of AAA when 
compared to patients with normal Hcy (Halazun et al, 2007).  
Two further known polymorphisms exist in the MTHFR gene. The T1317C polymorphism 
has been found to show no association with vascular disease. A1298C alone influences 
neither folate status or Hcy levels. However, compound heterozygosity for the C677T and 
A1298C alleles can be associated with decreased folate concentrations and raised levels of 
Hcy (Sunder-Plassman & Fodinger, 2003). To date there has been no link demonstrated 
between the A1298C allele and AAA. 
5.2 Other genes effecting homocysteine metabolism 
In addition to genetic errors effecting folate metabolism and causing subsequent hyperHcy, 
it is worth mentioning that hyperHcy can also result from genetic mutations in the genes 
encoding cystathione beta-synthase (the enzyme responsible for the trans-sulphuration of 
Hcy to cysteine) and enzymes responsible for B12 metabolism or absorption (the co-factor 
required for remethylation of Hcy to methionine) (Guilliams, 2004).  
These mutations occur at a significantly lower frequency than those in the MTHFR gene and 
are classically associated with severe hyperHcy, leading to clinical features including 
marfanoid features, mental retardation and early onset of vascular disease (Lievers et al, 2003).  
6. Genetics and AAA 
The burden of evidence for genetic influence on the aetio-pathogenesis of aneurysmal 
disease is small.  Genetic links have been shown in the initiation and formation of 
abdominal aortic aneurysms (AAA).  There have also been studies showing genetic evidence 
of familial clustering of AAA (Johansen & Koepsell, 1986).  
It is estimated that about 15% of patients with AAA without any recognizable connective 
tissue disorders, such as Ehlers-Danlos syndrome or Marfan syndrome, have a positive 
family history for AAA (Frydman et al, 2003; Rizzo et al, 1989). A few studies favoured a 
genetic model in explaining the familial aggregation of AAA and suggested the presence of 
a major gene effect.  However, these studies do not agree on whether the gene inheritance is 
recessive or dominant. 
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Finding a familial susceptibility gene could lead to easy identification of individuals prone 
to AAA’s due to the fact that AAA’s are largely asymptomatic prior to their rupture.  The 
study of gene pathways may also provide potential new targets for pharmacological 
intervention. 
It is difficult to independently assess familial tendency by gene analysis due to the presence 
of confounding overlap by other risk factors that have been described to have a genetic 
predisposition such as hypertension and atherosclerosis. 
6.1 Candidate genes and AAA 
If sibling risk results from genetic susceptibility, it may be inferred that this would be 
attributable to a few gene polymorphisms.  Candidate genes for AAA that have been 
investigated in population studies include those encoding type III collagen, matrix metallo-
proteinases and protease inhibitors, angiotensin converting enzyme, nitric oxide synthase 
and HLA loci.  Mutations in any of these candidate genes may explain the hereditary 
background of AAA (Thompson et al, 2008; Sandford et al, 2007).  
There are several plausible candidate genes implicated in the pathogenesis of AAA.  IL15 
(interleukin 15; a plausible candidate gene with respect to inflammation in AAA), GAB1 
(GRB2-associated binding protein 1; an important mediator of branching tubulogenesis and 
a central protein in cellular growth response, transformation, and apoptosis), and EDNRA 
(endothelin receptor type A; an endothelin-1 receptor expressed in many human tissues 
with the highest level in the aorta) around 140 cM on chromosome 4, as well as LRP3 (LDL 
receptor–related protein 3), HPN (transmembrane protease, serine 1; a serine-type peptidase 
involved in cell growth and maintenance), PDCD5 (programmed cell death 5; a protein 
expressed in tumor cells during apoptosis independent of the apoptosis-inducing stimuli), 
and PEPD (peptidase D; an Xaa-Pro dipeptidase important in collagen catabolism) on 
chromosome 19. 
Candidate gene studies have certainly shown causal pathways predisposing to developing 
AAA. Isolated mutations of one of several candidate genes are seen in some patients with 
AAA. But those did not always translate to similar mutations in first-degree relatives who 
were found to have AAA.  
6.1.1 ACE gene 
The renin-angiotensin-aldosterone (RAS) system plays a major role in cardiovascular 
homeostasis at many levels. The angiotensin converting enzyme (ACE) converts angiotensin 
I into the active angiotensin II. In an animal model, infusion of angiotensin II produces large 
AAA (Daugherty et al, 2000), while ACE has been shown to be highly expressed in human 
aneurysmal aorta (Nishimoto et al, 2002). This suggests a role for increased local levels of 
angiotensin II in the pathogenesis of AAA and may explain the protective effect to the 
medial layers of the infra-renal aorta provided by treatment with captopril-
hydrochlorothiazide. This was shown to reduce MMP activity, both directly and by 
inhibiting the release of the MMP activator Angiotensin II from smooth muscle cells (Moroz 
et al, 2007). This suggests a role for ACE-inhibitors in the treatment and prevention of AAA. 
There is a polymorphic site in the ACE gene which consists of the presence or absence of 287 
base pairs. It has been termed ‘I’ for insertion of the fragment or ‘D’ for its deletion. The 
polymorphism accounts for three genotypes (DD and II homozygotes and ID heterozygotes. 
Because the alleles are co-dominant with an additive effect on plasma levels, DD 
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homozygotes have the highest plasma levels of ACE, while II homozygotes have the lowest 
(Thompson et al, 2008; Sandford et al, 2007; Fatini et al, 2005). Patients in whom the 
polymorphism is present have been found to have a 50% reduction in ACE levels with 
subsequent reduction of angiotensin II levels (Fatini et al, 2005). Given the physiological 
processes undertaken by these enzymes, it fits therefore that the D allele has been associated 
with hypertension and IHD. 
More recently, an association with AAA has been demonstrated by several studies who 
have found a significantly increased D allele frequency in AAA patients compared to 
controls (Fatini et al, 2005a). Furthermore, it has been shown that this polymorphism affects 
AAA development independently of any association with blood pressure (Pola et al, 2001). 
Interestingly, aldosterone does not mediate angiotensin induced increases in AAA diameter. 
This suggests that increased ACE levels found in aneurysmal wall may be independent of 
the physiological RAS system (Cassis et al, 2005).  
6.1.2 Nitric oxide synthase gene 
Nitric oxide (NO) contributes to vessel homeostasis by inhibiting vascular smooth muscle 
contraction and growth, platelet aggregation, and leukocyte adhesion to the endothelium. 
Humans with atherosclerosis, diabetes, or hypertension often show impaired NO pathways 
(Dessy & Ferron, 2004). 
Endothelial Nitric Oxide Synthase (eNOS) is responsible for the production of NO. Several 
polymorphisms have been identified in the gene coding for eNOS and these may affect the 
function of the enzyme. 
One polymorphism consists of a 27 base pair repeat, present in intron 4 of the eNOS gene. 
Commonly, 5 repeats are identified at this polymorphic site, however, when analysing 
patients with AAA, it was found that 4 repeats at this site may be associated with rapid 
progression of AAA (Kotani et al, 2000). 
A further polymorphism is the G894T, in which the rarer T allele has been found to be more 
frequent in AAA patients compared with age/sex-matched controls (Fatini et al, 2005b). The 
reduction in NO tissue levels resulting from the T-allele has been suggested to contribute to 
AAA formation (Thompson et al, 2008). 
6.1.3 Chemokine receptor genes 
Chemokines are a family of small secreted proteins that selectively recruit monocytes, 
neutrophils, and lymphocytes to sites of vascular injury, inflammation, and developing 
atherosclerosis.  
Recently, a polymorphism of the chemokine receptor gene 5 (CCR5) has been identified. 
This is a 32 base pair deletion in the promoter region of the gene, resulting in reduced 
receptor expression, inhibition of leukocyte recruitment and reduction of inflammatory 
infiltrate (Smith et al, 1997). This deletion polymorphism has been investigated in 
vasculopaths with a higher incidence detected among AAA patients compared with patients 
exhibiting peripheral arterial or carotid disease and healthy controls (Ghilardi et al, 2004). 
6.1.4 Interleukin genes 
Adventitial and medial inflammatory responses have been implicated as playing a key 
role in AAA pathogenesis (Arapoglou et al, 2009). Interleukins are associated with this 
inflammatory process and studies have investigated a link between interleukin gene 
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polymorphisms and AAA. Only the gene encoding the anti-inflammatory cytokine IL-10 
was found to have a polymorphism expressed more frequently in AAA patients than 
controls. It is felt the reduced production of IL-10 as a result of this polymorphism impairs 
the ability to regulate inflammatory processes, leading to AAA formation (Bown et al, 
2003).  
6.1.5 Human leukocyte antigen genes 
The Human Leukocyte Antigen (HLA) system is a genetically determined series of antigens 
that are expressed on leukocytes and tissues. They control a variety of cell-cell interactions 
and certain subtypes have been associated with chronic inflammatory conditions such as 
rheumatoid arthritis (Sandford et al, 2007).  
An autoimmune component to the pathogenesis of AAA has been proposed, implicating 
HLA subtypes. In a Japanese population, an increased frequency of the HLA-DR2(15) allele 
has been demonstrated in aneurysm patients. Other studies have shown HLA-DR B1*02 and 
B1*04 subtypes as well as HLA-A2 and HLA-B61 antigens to be more common in AAA 
patients (Rasmussen et al, 2002; Monux et al, 2003; Hirose et al, 1998). Despite this, a more 
recent study of 241 AAA patients failed to demonstrate a risk association between AAA and 
these alleles suggesting that the role of these particular genes and the autoimmune 
component in AAA etiology does not appear to be as crucial as previously proposed 
(Badger et al, 2007). 
Several additional candidate gene association studies have been performed in AAA 
patients in genes encoding proteins ranging from collagen to heme-oxygenase. No 
statistically significant difference has been observed in such studies, however, the 
evolution of genetic analysis is likely to uncover several new potential genetic links to 
AAA in years to come.  
Inevitably, whole human genome studies in the future will identify a combination of 
polymorphisms contributing to the pathogenesis of AAA and it is unlikely that a single gene 
will underpin this process. 
6.2 Collagen and AAA 
Collagen (type I and III) is the principle component of the aortic adventitia. The tensile 
characteristics are attributed to type III collagen and the load-bearing characteristics to type 
I collagen. The tensile strength of the aortic wall can be influenced by synthesis of 
structurally abnormal type III collagen that constitutes the basis for the aneurysm formation 
(Rizzo et al, 1989). A mutation of the Type III collagen gene could result in inherited 
propensity to develop AAA (Kontusaari et al, 1990).   
Abdominal aortic aneurysms, dissections and ruptures are common disorders in different 
syndromes that are caused by collagen defects. Phenotypic overlap of heritable disorders of 
connective tissue might be a possible explanation of familial aneurysms. Ehlers Danlos 
Syndrome (EDS) IV is caused by genetically determined type III collagen (COL3A1) defect 
or a deficiency.  There were some initial studies that correlated levels of Type III collagen 
and AAA, suggesting even that some of the familial AAA patients could be a manifestation 
of a subclinical EDS IV.  Subsequent studies measuring Type III collagen levels in family 
members of patients with AAA were inconclusive to suggest a causal relationship between 
familial clustering and type III collagen. 
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6.3 Aneurysmal disease in twins 
The sibling risk for developing AAA has led to research into associations of AAA in twins.  The 
most significant study is from the Swedish Twin Registry.  The investigators provide robust 
epidemiologic evidence that heritability contributes to aneurysm formation.  Concordances and 
correlations were significantly higher in MZ (monozygotic, identical) compared with DZ 
(dizygotic, non-identical) compared with DZ twins, indicating genetic effects.  There was a 24% 
probability that the MZ twin of a person with an AAA will have the disease. The twin of an MZ 
twin with an AAA had a risk of an AAA that was 71 times that of the MZ twin of a person 
without an AAA. When looking at twins over the age of 55 with an AAA, then possibly 
excluding genetic connective tissue disorders such as Ehlers-Danlos and Marfan syndrome, the 
odds ratio was still significantly higher for MZ twins compared to DZ twins. They noted that in 
other regions the proportions of type of effects could differ because of environmental factors. 
Also in the cases of aneurysmal disease with several genetic and environmental factors, the 
liability model assumes that the disease will occur when there are enough contributory factors 
to push the individual's liability above the threshold (Wahlgren et al, 2010).  
The familial clustering of AAA is unlikely to be due to chance alone; the odds ratios for sibling 
risk in case–control studies are too high. But almost 20 years of work has yielded little 
persuasive evidence for specific genes underlying this phenomenon. Large, collaborative 
research proposals are needed to address the reasons for familial clustering of AAA. 
7. Therapeutic interventions on homocysteine 
The detection of elevated levels of Hcy in patients with large, symptomatic AAA is unlikely 
to change the treatment because such patients need repair of their AAA. It is in the 
management of small (30-50mm) AAA’s that Hcy levels may have a role. Although surgery 
is not indicated for these AAA’s, a proportion will expand until they are large enough to 
warrant elective intervention before rupture occurs. Current practice is to monitor the 
diameter of AAA’s with periodic ultrasound or CT scanning, but our understanding of the 
natural history of these aneurysms remains incomplete.  
The identification of risk factors such as Hcy that are associated with greater rates of 
expansion, may help in the planning of AAA surveillance, the identification of high risk 
patients who may benefit from early intervention and the development of strategies to 
prevent expansion (Halazun et al, 2007).  
To briefly review the metabolism of Hcy, we know that B12 and folic acid are required for 
transmethlyation to methionine and that B6 is required for trans-sulphuration to 
cystathionine. Deficiencies of these vitamins have been implicated with hyperHcy, while 
normal levels of folate, even in the presence of the MTHFR polymorphism seem to be 
sufficient to regulate Hcy levels. In fact, it has been proposed that the single most important 
determinant of Hcy levels in the general population is folate status (Castro et al, 2006).  
It seems logical therefore that supplementation with folic acid and vitamins B6 and B12 
could act as Hcy lowering therapies, potentially preventing the progression/onset of 
aneurysmal disease (a risk factor reduction technique). 
7.1 Folate, B6 and B12 supplementation 
Dietary supplementation with folate has been shown to reduce Hcy levels on average by 
25% in individuals with cardiovascular disease. Further reduction in levels has been 
www.intechopen.com
 Diagnosis, Screening and Treatment of  
Abdominal, Thoracoabdominal and Thoracic Aortic Aneurysms 
 
46
demonstrated with the addition of B6 and B12, suggesting a synergistic effect. Such a 
reduction in Hcy has previously been linked to an 11% lower risk of coronary heart disease 
and 19% lower risk of stroke. Despite this, collective evidence recently published in a large-
scale meta-analysis suggests that treating hyperHcy with folate and other B-vitamins had no 
significant effects within 5 years on cardiovascular morbidity and mortality (Clarke et al, 
2010). 
Interestingly, these results are associated with patients who already have established 
cardiovascular disease and may be explained by the potential detrimental effects of B 
vitamin supplementation. In patients with established atherosclerotic disease it is suggested 
that B vitamins have the potential to enhance inflammation and proliferation in 
atherosclerotic lesions (Smulders & Blom, 2011). In contrast to this, several animal studies 
have suggested that B vitamins delay initial development of atherosclerosis. This is 
supported by a study in which healthy siblings of patients with premature atherosclerotic 
disease received dietary folate and B6 supplementation for 2 years, a reduced frequency of 
abnormal exercise stress tests was detected, which is associated with a reduced risk of 
ischaemic coronary events. This suggests that Hcy lowering therapy as prophylaxis for at 
risk patient groups may be beneficial. One such group are patients with small AAA’s, in 
who hyperHcy has been linked with more rapid rate of expansion (Halazun et al, 2007), or 
indeed patients with familial AAA disease who are at high risk of AAA. 
7.2 Trimethylglycine (Betaine) 
Trimethylglycine (TMG) is a small trimethylated amino acid that can react with the enzyme 
betaine methyl-transferase, donating a methyl group to remethylate Hcy to methionine 
(Steenge et al, 2003). 
Moderate Hcy lowering effects have been demonstrated, however, this requires high dose 
(>6gm/day) TMG and it is not as effective as folate supplementation. To date, TMG 
administration has not been shown to lower the risk of cardiovascular disease, however, 
studies are continuing (Steenge et al, 2003). 
7.3 N-Acetyl Cysteine (NAC) 
NAC is a pharmaceutical drug and nutritional supplement used primarily as a mucolytic 
agent for the treatment of paracetamol overdose. Recently it has been shown to increase 
plasma free Hcy, the form removed by the kidney, by breaking the disulfide links of the 
bound form. 
One recent study randomised patients with confirmed hyperHcy and coronary artery 
disease to 5mg folic acid, 600mg NAC or placebo daily for 8 weeks. Both folic acid and NAC 
had a similar Hcy lowering effect and improved endothelial function compared to placebo 
(Yilmaz et al, 2007). A further study found that plasma Hcy levels were reduced during 
treatment with NAC by 45% (Wiklund et al, 1996).  
NAC might therefore be a highly efficient nutritional supplement for reducing plasma Hcy 
and further research large scale randomised trials are required to identify a potential benefit 
in lowering risk of aneurysmal and cardiovascular disease. 
7.4 Omega-3 Polyunsaturated Fatty Acids (PUFA’s) 
A growing body of research on marine lipids has revealed that omega-3 rich fish oil 
supplementation can reduce elevated Hcy levels. 
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An animal model study examined the effect of fish oil rich in omega-3 PUFA’s on Hcy 
metabolism, treating rats with olive oil, tuna oil or salmon oil for 8 weeks. The plasma Hcy 
level was significantly reduced in the group fed tuna oil, rich in omega-3 PUFA’s (Huang et al, 
2011). Similarly, a human trial randomised patients with type 2 diabetes mellitus to either 3g of 
omega-3 PUFA’s or placebo daily for two months. Hcy levels were found to decrease 
significantly in the treatment group compared with those receiving placebo (Pooya et al, 2010). 
7.5 Taurine 
Taurine is an organic acid and a major constituent of bile. It is a derivative of the sulphur 
containing amino acid cysteine and is one of the few known naturally occurring sulfonic acids. 
Recent studies have shown that taurine can block methionine absorption from the diet, 
thereby reducing available substrate for Hcy synthesis. One animal study found that taurine 
normalised hyperHcy and reduced atherosclerosis by 64% over control animals (Zulli, 2011). 
While in a study of healthy, middle-aged women, plasma Hcy levels exhibited a significant 
decline after taurine supplementation (Ahn, 2009). The investigators concluded that 
sufficient taurine supplementation might effectively prevent cardiovascular disease. 
8. Conclusion 
The pathogenesis of abdominal aortic aneurysm is complex and multi-factorial. The true 
mechanism underlying the disease process is likely to be underpinned by an interaction 
between a genetic predisposition and environmental risk factors including smoking and 
hypertension. 
HyperHcy and polymorphisms in the MTHFR gene have been implicated as risk factors for 
cardiovascular disease and there is some evidence that raised levels of Hcy are associated 
with an increased risk of having an AAA. Despite this, on the current evidence available, we 
can not confidently state that hyperHcy is a causative factor in the pathogenesis of AAA, 
although it may help to explain the variation in expansion rates.  
In addition to studies of the MTHFR gene, recent candidate gene analysis has provided us 
with an improved understanding of the genetic predisposition to AAA development. It is 
unlikely however, that a single gene polymorphism will hold the key to aneurysm 
formation and such analysis is susceptible to confounding influences of genetic 
stratification, in particular genetic overlap with risk factors such as hypertension. 
Unanswered questions will remain until large scale genome wide association studies are 
undertaken to enable a complete understanding of the genetic influence on the pathogenesis 
of AAA. 
With regard to the medical management of AAA, the current available evidence would 
suggest that pharmacotherapy with statin and ACE-Inhibitor should be implemented to 
attenuate aneurysmal expansion. Macrolides and NSAID’s may play a similar role and are 
currently being investigated.  
There is insufficient evidence to support the routine use of B6, B12 and folate 
supplementation, though multicentre, prospective randomised trials are urgently 
recommended. This also applies to the use of PUFA’s, NAC and taurine.  
Ultimately, as these studies progress and our understanding of the pathophysiology of AAA 
evolves, it is likely that additional pharmacological and dietary supplements will be 
identified to form an armamentarium aimed at the prevention of AAA rupture. 
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